CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies	B-cell acute lymphoblastic leukemia, B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Leukemia, B-Cell, Neoplasms by Histologic Type, Tumor Virus Infections, diffuse large B-cell lymphoma, hematologic disorder, high grade B-cell lymphoma, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm, non-Hodgkin lymphoma, viral infectious disease	Recruiting	Phase 1	2026-04-03		NCT06208735

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
British Columbia Cancer Agency	58

7 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Alberta Children's Hospital	Calgary	Canada	70
Arthur J.E. Child Comprehensive Cancer Centre	Calgary	Canada	45
BC Children's Hospital	Vancouver	Canada	10
Princess Margaret Cancer Centre	Toronto	Canada	22
The Hospital for Sick Children	Toronto	Canada	20
The Ottawa Hospital - General Campus	Ottawa	Canada	31
Vancouver General Hospital	Vancouver	Canada	53